comparemela.com
  1. Home
  2. Live Updates
  3. Phase 1 2 Linker Mm1 Trial - Breaking News

Latest Breaking News On - Phase 1 2 linker mm1 trial - Page 1 : comparemela.com

Decreasing Grade 3/4 Infections, Limited Hospitalizations Underscore Potential for Linvoseltamab in R/R Myeloma

Sundar Jagannath, MBBS, discusses linvoseltamab and expands on key efficacy and safety findings from the LINKER-MM1 trial in patients with relapsed/refractory multiple myeloma.

New yorkUnited statesSundar jagannathTisch cancer institute of mount sinaiMultiple myelomaMedical oncologyTisch cancer instituteMount sinaiPhase 1 2 linker mm1 trial

EMA Accepts Marketing Authorization Application for Linvoseltamab in R/R Multiple Myeloma

The EMA has accepted for review an MAA seeking the approval of linvoseltamab for use in select patients with relapsed/refractory multiple myeloma.

United statesEuropean medicines agencyRegeneron pharmaceuticals incAmerican society of hematologyMultiple myelomaRelapsed refractory multiple myelomaEuropean medicines agencyMarketing authorization applicationPhase 1 2 linker mm1 trial

Dr Richter on the Optimal Dosing Schedule of Linvoseltamab in Multiple Myeloma

Joshua Richter, MD, discusses findings from the phase 1/2 LINKER-MM1 trial (NCT03761108) in multiple myeloma.

Joshua richterBlavatnik family chelsea medical centerDivision of hematologyTisch cancer instituteMedical oncologyMultiple myelomaMount sinaiPhase 1 2 linker mm1 trialRelapsed refractory multiple myeloma2023 international myeloma society annual meeting

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.